← All trials
NCT06673329
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2024
- Primary completion
- May 31, 2026
- Completion date
- Nov 30, 2026
- First posted
- Nov 4, 2024
- Last posted
- Nov 4, 2024
- Enrollment
- 11
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Columbia UniversityLead sponsor
- Columbia UniversityOfficial
- Columbia UniversitySponsor investigator
- Bausch Health CompaniesCollaborator
Drugs studied
Indications studied
- Brain Neoplasms
- Breast Neoplasms
- Colonic Neoplasms
- Esophageal Neoplasms
- Genital Neoplasms, Female
- Head and Neck Neoplasms
- Kidney Neoplasms
- Liver Neoplasms
- Lung Neoplasms
- Mouth Neoplasms
- Neoplasms
- Pancreatic Neoplasms
- Prostatic Neoplasms
- Rectal Neoplasms
- Skin Neoplasms
- Stomach Neoplasms
- Testicular Neoplasms
- Thyroid Neoplasms
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.